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Abstract
Background: Cardiovascular disease is the leading cause of mortality among patients with serious mental illness (SMI) and
the prevalence of metabolic syndrome—a constellation of cardiovascular risk factors—is significantly higher in these
patients than in the general population. Metabolic monitoring among patients using second generation antipsychotics
(SGAs)—a risk factor for metabolic syndrome—has been shown to be inadequate despite the release of several guidelines.
However, patients with SMI have several factors independent of medication use that predispose them to a higher
prevalence of metabolic syndrome. Our study therefore examines monitoring and prevalence of metabolic syndrome in
patients with SMI, including those not using SGAs.
Methods and Findings:We retrospectively identified all patients treated at a Veterans Affairs Medical Center with diagnoses
of schizophrenia, schizoaffective disorder or bipolar disorder during 2005–2006 and obtained demographic and clinical
data. Incomplete monitoring of metabolic syndrome was defined as being unable to determine the status of at least one of
the syndrome components. Of the 1,401 patients included (bipolar disorder: 822; schizophrenia: 222; and schizoaffective
disorder: 357), 21.4% were incompletely monitored. Only 54.8% of patients who were not prescribed SGAs and did not have
previous diagnoses of hypertension or hypercholesterolemia were monitored for all metabolic syndrome components
compared to 92.4% of patients who had all three of these characteristics. Among patients monitored for metabolic
syndrome completely, age-adjusted prevalence of the syndrome was 48.4%, with no significant difference between the
three psychiatric groups.
Conclusions: Only one half of patients with SMI not using SGAs or previously diagnosed with hypertension and
hypercholesterolemia were completely monitored for metabolic syndrome components compared to greater than 90% of
those with these characteristics. With the high prevalence of metabolic syndrome seen in this population, there appears to
be a need to intensify efforts to reduce this monitoring gap.
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Introduction
Patients with serious mental illness die an average of twenty
to thirty years earlier than the general population [1], with
cardiovascular disease the leading cause of mortality for patients
with schizophrenia [2] and bipolar disorder [3]. Metabolic
syndrome is a constellation of cardiovascular risk factors including
diabetes, hypertension, obesity and dyslipidemia [4], is potentially
reversible and may explain the higher incidence of cardiovascular
disease in patients with serious mental illness. According to the
Third National Health and Nutrition Examination Survey, the
age-adjusted prevalence of metabolic syndrome as defined by the
US National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III) was 23.7% in the general population
[5]. In contrast, a recent large study of psychiatric outpatients
including patients with schizophrenia, bipolar disorder, and
depression revealed a metabolic syndrome prevalence of 52% [6].
This high prevalence of metabolic syndrome seen in psychiatric
patients has been partially attributed to the use of second gene-
ration antipsychotics [7,8], especially in patients with schizophre-
nia. Several expert consensus guidelines have therefore called for
routine monitoring of weight, lipids and glucose for patients taking
second generation antipsychotics [9,10]. Despite this, studies have
shown that monitoring of metabolic syndrome components and
subsequent treatment among psychiatric patients using second
generation antipsychotics remains inadequate, with monitoring of
different components of metabolic syndrome ranging from 0% to
70% [11,12,13,14,15,16,17,18,19,20]. One recent study showed
that monitoring failed to improve in patients taking antipsychotics
even after the release of Food and Drug Administration (FDA)
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warnings and American Diabetic Association/American Psychi-
atric Association (ADA/APA) recommendations [21]. There are
however no large studies that have examined monitoring of
metabolic syndrome in patients with serious mental illness not
using antipsychotic medications. While antipsychotic use is an
important contributor to increased prevalence of metabolic
syndrome among psychiatric patients, several other important
factors such as physical inactivity [22,23], poor diet [24], and
cigarette use [25,26] are also more prevalent in these patients and
the presence of metabolic abnormalities has been reported in small
studies of drug-naı¨ve psychiatric patients [27,28]. The Mount
Sinai Conference has therefore suggested that all patients with
schizophrenia should be considered to be at high risk for coronary
heart disease and recommended routine screening for hyperlipi-
demia [29]. However high prevalence of metabolic syndrome is
not limited to just patients with schizophrenia; patients with other
serious mental illnesses such as bipolar disorder and schizoaffective
disorder have also been shown to have a high prevalence of
metabolic syndrome ranging from 30–70% [6,30,31]. This high
prevalence seen in patients with different serious mental illnesses
suggests that routine monitoring of the different components of
metabolic syndrome in all such patients would not only be
essential for early management of cardiovascular risk, but may also
help guide initiation of medications such as second generation
antipsychotics. Due to the aggregate nature of the syndrome,
adequate monitoring for a high risk patient requires monitoring of
all components of the syndrome to help guide management.
However, the current literature has yet to address the present state
of monitoring efforts for all the metabolic syndrome components
being employed for patients with serious mental illnesses,
especially those not using antipsychotic medications.
Our study therefore expands on these previous studies by
examining rates of monitoring for the different components of
metabolic syndrome and documents the prevalence of metabolic
syndrome in patients with serious mental illness, including those
not using second generation antipsychotics. For this purpose, we
studied the number of patients who were not completely
monitored for the five components of metabolic syndrome in a
large sample of patients with a diagnosis of bipolar disorder,
schizoaffective disorder or schizophrenia who received treatment
at a Veterans Affairs (VA) Medical Center over a two-year period,
and the prevalence of metabolic syndrome in those who were
completely monitored.
Methods
The Institutional Review Board (IRB) at the Providence VA
Medical Center reviewed and approved all the procedures
described in this protocol. Detailed patient information from this
study was compiled by an automated search strategy using the
hospital’s electronic medical record system called Veterans Health
Information Systems and Technology Architecture (VISTA). As a
research tool, VISTA provides comprehensive and reliable
patient-level clinical data across the spectrum of care and its use
in research has been validated in previous trials [32,33]. A
database query of the electronic medical record was used to
identify all patients with diagnoses of schizophrenia, schizoaffec-
tive disorder or bipolar disorder treated as inpatients or
outpatients at the Providence VA Medical Center during calendar
years 2005–2006. The study population was identified through
structured search of the electronic medical records based on ICD-
9 codes. This project obtained approval from the Providence VA
Medical Center IRB for waiver of written informed consent as the
research involves no more than minimal risk to the subjects, the
waiver of consent would not adversely affect the rights and welfare
of the subjects and the research could not be practicably carried
out without the waiver.
The database query included only those patients who had at
least one mental health visit or hospitalization during calendar
years 2005–2006, so that only patients with active utilization of the
VA Medical Center services would be studied. All patients were
divided into three groups based on their psychiatric diagnosis –
bipolar, schizoaffective or schizophrenia. Patients who had
overlapping diagnoses of schizoaffective disorder with either
bipolar disorder or schizophrenia were assigned to the schizoaf-
fective disorder category [34]. Exclusion criteria included patients
with no mental health visits or hospitalizations during calendar
years 2005–2006 and patients who had diagnoses of both bipolar
disorder and schizophrenia without a diagnosis of schizoaffective
disorder.
Metabolic syndrome was defined using the NCEP ATP III
guidelines [4], and consisted of meeting at least 3 out of 5 of the
following criteria: (1) fasting plasma glucose $5.6 mmol/L
(100 mg/dL) or taking anti-hyperglycemic medication, (2) triglyc-
erides $1.7 mmol/L (150 mg/dL), (3) high density lipoprotein
(HDL) cholesterol ,1.0 mmol/L (40 mg/dL) for men and
,1.3 mmol/L (50 mg/dL) for women, (4) systolic blood pressure
$130 mm Hg and/or diastolic blood pressure $85 mm Hg or
taking antihypertensive medication, and (5) central obesity with
waist .102 cm (40 inches) for men and .88 cm (35 inches) for
women. In line with previous studies [35], we used a modified
ATP III criteria that substituted a body mass index (BMI)$30 for
waist circumference since data for the latter was not available.
Data collected from the medical record included demographic
variables, psychiatric diagnoses, previous diagnoses of hyperten-
sion, hypercholesterolemia, diabetes, stroke, or coronary angio-
plasty or bypass surgery, biological variables such as BMI, systolic
and diastolic blood pressures, total cholesterol, high density
lipoprotein and low density lipoprotein (LDL) cholesterols,
triglycerides, blood glucose, and hemoglobin A1c (HbA1c),
smoking status, number of primary care provider (PCP) visits,
employment and marital status, and Global Assessment of
Functioning (GAF) score. Data was gathered for psychotropic
medications (first and second generation antipsychotics, antide-
pressants, anticonvulsants, lithium, and benzodiazepines), antihy-
pertensive medications and, anti-hyperglycemic medications. A
patient was considered to have been incompletely monitored for
metabolic syndrome if information required to determine the
status of any one of the metabolic syndrome components,
according to the modified ATP III criteria as listed above, was
not available in the database query. Past diagnoses of hyperten-
sion, hypercholesterolemia and diabetes were not used to
determine metabolic syndrome components, which were based
on biological and medication variables from the two year study
period.
Outcomes
The main outcome of interests are the percentage of the sample
population who were not monitored for all of the metabolic
syndrome components and the prevalence rates of metabolic
syndrome as defined by the modified ATP III criteria (BMI in
place of waist circumference) among the three psychiatric groups
for patients who were completely monitored for all five metabolic
syndrome components.
Statistical Procedures
After dividing patients into the three psychiatric diagnosis
groups, we compared baseline characteristics, past medical history
Metabolic Monitoring in Serious Mental Illness
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and medication prescription between the bipolar disorder,
schizophrenia and schizoaffective disorder diagnostic groups.
Comparisons were made using chi-square likelihood ratio tests
for categorical variables or ANOVA for continuous variables. We
then determined the number of patients not monitored for the five
metabolic syndrome components and then compared psychiatric
diagnoses, demographic variables, past medical history and
psychiatric medications between patients who were incompletely
monitored for metabolic syndrome and those who were com-
pletely monitored using paired Student’s t-tests or likelihood ratio
Chi-square tests. We then constructed a multivariate logistic
regression model with incomplete monitoring as the outcome and
included age, GAF, service connection, previous diagnoses of
hypertension, hypercholesterolemia and diabetes and second
generation antipsychotic prescription as independent variables as
these are likely associated with monitoring for metabolic syndrome
based on previous literature [13,20], severity of serious mental
illness [36] and likely engagement with VA providers. For patients
who were monitored for all metabolic syndrome components, we
compared the proportion of patients who met criteria for
metabolic syndrome among the three psychiatric groups. We also
calculated age-adjusted prevalence rates of metabolic syndrome
using the 2000 United States census as the standard population to
allow for direct comparisons with the current prevalence of
metabolic syndrome in the general United States population. All
statistical analyses were conducted using SAS JMPH (SAS
Institute, Inc., Cary, NC). All P values were 2-sided, and a p-
value of 0.05 or less was considered significant. Data was presented
as mean 6 standard deviation and odds ratios (OR) were reported
with 95% confidence intervals (CI).
Results
A total of 1411 patients were identified by the database query.
Of these, 10 patients had diagnoses of both bipolar disorder and
schizophrenia without having a diagnosis of schizoaffective
disorder and were excluded from the study population. Of the
1401 included patients, 822 were placed in the bipolar disorder
category, 222 in the schizophrenia category and 357 in the
schizoaffective disorder category. Characteristics of the patients in
these three are shown in Table 1. The mean age for the three
groups was significantly different (55.7612.8 years for the bipolar
group, 60.0611.8 years for the schizophrenia group and
53.2610.2 years for the schizoaffective disorder group) and all
three diagnostic groups were predominantly male in similar
proportions. There were also significant differences among the
three groups in marital status, employment status, active smoking
status and GAF. Among the biological variables collected, only
BMI differed significantly between the three groups, with the
schizoaffective group having the highest BMI (30.365.8 kg/m2)
compared to the bipolar and schizophrenia groups (29.865.7 kg/m2
and 28.967.3 kg/m2 respectively). There were significant differenc-
es among prescription of all psychiatric medication classes recorded
except benzodiazepines, notably with the highest rate of second
generation antipsychotic prescription occurring in the schizoaffective
group (84.9%) compared to the bipolar and schizophrenia groups
(49.6% and 63.1% respectively).
The number of patients in our study population who were not
monitored for the five different metabolic syndrome components
are listed in Table 2. Of the 1401 study subjects, 300 (21.4%) were
not monitored for at least one of the five metabolic syndrome
components. Additionally, 17.9% were not measured for any lipid
levels (total cholesterol, triglycerides, HDL and LDL levels). A
comparison of the 300 patients with incomplete monitoring (not
monitored for at least one of the five metabolic syndrome
components) with the other 1101 patients is shown in Table 3.
There were no significant differences between these two groups in
the rates of assignment to any particular psychiatric diagnosis,
GAF scores, service connection and number of PCP visits over the
two year period. There were significant differences, however,
among the proportion of patients having previous diagnoses of
hypertension, hypercholesterolemia and diabetes, with patients
monitored for all metabolic syndrome components having
significantly higher prevalence of these diseases(47.6%, 58.4%
and 24.4% respectively) than those incompletely monitored
(23.7%, 20.3% and 11.0% respectively; p,0.05 for all 3 disease
states). Additionally, rates of prescription of psychiatric medica-
tions were also significantly different between the two groups, with
patients completely monitored more likely to have been prescribed
second generation antipsychotics and also antidepressants, anti-
convulsants, and benzodiazepines.
In the multivariate logistic regression model with incomplete
monitoring as its outcome and age, GAF, service connection,
previous diagnoses of hypertension, hypercholesterolemia and
diabetes and second generation antipsychotic prescription as
independent variables, previous diagnoses of hypertension and
hypercholesterolemia and prescription of second generation
antipsychotics were the only variables significantly associated with
incomplete monitoring (OR=0.73, 95% CI= 0.57 to 0.93;
OR=0.54, 95% CI= 0.42 to 0.66; and OR=0.71, 95%
CI= 0.57 to 0.88 respectively). Of patients who were not
prescribed second generation antipsychotics and did not carry
previous diagnoses of hypertension or hypercholesterolemia, only
54.8% were monitored for all five components of metabolic
syndrome compared to 92.4% of patients who were prescribed
second generation antipsychotics and carried previous diagnoses of
both hypertension and hypercholesterolemia and 77.8% of
patients who had at least one of these three characteristics.
For the 1101 patients who were monitored for all five
components of metabolic syndrome, there were significant
differences among the three psychiatric diagnostic groups in the
prevalence of each of the metabolic syndrome components except
triglycerides and in the number of metabolic syndrome compo-
nents for which criteria were met (Table 4). However, the overall
prevalence of metabolic syndrome was not significantly different
among the mental illnesses: 57.1% for bipolar disorder, 50.0% for
schizophrenia and 61.0% for schizoaffective disorder. Using the
2000 United States census, the overall age-adjusted prevalence
rate of metabolic syndrome for the study population was 48.4%,
with prevalence rates of 46.6%, 42.1% and 56.7% for bipolar
disorder, schizophrenia and schizoaffective disorder respectively.
Discussion
With cardiovascular disease being the leading cause of mortality
among patients with serious mental illness, monitoring for
metabolic syndrome, a major modifiable risk factor for cardiovas-
cular mortality, is paramount for early detection and management.
Since previous studies have focused solely on psychiatric patients
using second generation antipsychotics, our study investigated
current monitoring rates of metabolic syndrome in a large number
of patients with serious mental illness, including patients not using
antipsychotic medications. Our study showed that one fifth of the
study population was not monitored for at least one of the five
metabolic syndrome components over a two year period.
However, only half of the patients who were not prescribed
second generation antipsychotics and were not diagnosed with
hypertension or hypercholesterolemia previously were monitored
Metabolic Monitoring in Serious Mental Illness
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for all metabolic syndrome components compared to 92.4% of
patients who had all three of these characteristics. Among the
patients who were completely monitored for metabolic syndrome,
the overall age adjusted prevalence of metabolic syndrome was
48.4%, grossly double that of the general United States population
[5].
The high prevalence of metabolic syndrome seen in patients
with serious mental illness, especially those taking second
generation antipsychotics, has led to the development of several
expert guidelines recommending routine metabolic monitoring in
patients using antipsychotics [9,10] and those with schizophrenia
[29]. Despite this, monitoring and treatment of various compo-
nents of metabolic syndrome for patients using antipsychotic
agents remains inadequate [11,12,13,14,15,16,17,18,19,20,21].
While our study showed that roughly 80% of patients with serious
mental illness were completely monitored for all components of
metabolic syndrome, monitoring was much lower in patients not
prescribed second generation antipsychotics and without a
previous history of hypertension or hypercholesterolemia. These
results are similar to one previous study which saw higher rates of
serum glucose and lipid testing in patients using second generation
antipsychotics who carried previous diagnoses of diabetes or
dyslipidemia [13]. The rates of monitoring of the different
metabolic syndrome components in our study are higher than
two previous studies examining monitoring of all metabolic
syndrome components in patients using second generation
antipsychotics which ranged from 0% to 40% [15,16]. The
overall higher monitoring rates in our study may be partially
explained by the organizational pursuit of more integrated health
care, especially between primary care and mental health services,
at a VA Medical Center compared to non-VA settings [37] where
most previous studies have been conducted. Specifically, co-
location of mental health and non-mental health services in one
setting, as occurs at a VA Medical Center, is associated with
improved health monitoring of mental health patients [38].
Additionally the use of performance measures in the Veterans
Health Administration to hold managers and clinicians account-
able for appropriate management and monitoring of chronic
Table 1. Patient Characteristics.
Bipolar (n =822) Schizophrenia (n=222) Schizoaffective (n =357) Total (n = 1401)
Age (years)* 55.7612.8 60.0611.8 53.2610.2 55.7612.3
Male 91.4% 93.6% 95.1% 92.5%
Married* 37.0% 13.2% 23.2% 29.7%
Employed* 46.9% 33.3% 34.4% 41.6%
Active Smoking* 49.7% 50.7% 57.5% 51.8%
GAF* 52.868.4 49.669.8 49.167.4 51.368.6
Past Medical History
Hypertension* 46.7% 39.2% 34.7% 42.5%
Hypercholesterolemia 51.1% 45.1% 51.5% 50.3%
Diabetes 20.6% 19.8% 24.9% 21.6%
Stroke 4.0% 4.5% 3.6% 4.0%
Heart Failure 2.4% 1.8% 3.6% 2.6%
Coronary Artery Bypass Graft* 2.7% 0.5% 0.6% 1.8%
Percutaneous Transluminal Coronary
Angioplasty
0.9% 0.5% 0.6% 0.7%
Biological Variables
Body Mass Index (kg/m2)* 29.865.7 28.967.3 30.365.8 29.866.0
Systolic Blood Pressure (mm Hg) 126.0615.7 125.0617.3 125.1616.5 125.6616.1
Diastolic Blood Pressure (mm Hg) 75.5610.3 74.1610.1 76.0610.7 75.4610.4
Hemoglobin A1c (%) 6.260.1 6.261.0 6.161.5 6.261.4
Total Cholesterol (mg/dL) 190.8645.5 184.7641.5 188.2644.2 189.2644.6
High Density Lipoprotein (mg/dL) 42.7613.3 43.8611.4 41.1611.8 42.4612.7
Low Density Lipoprotein (mg/dL) 113.0637.2 108.8634.8 113.4638.2 112.5637.1
Triglycerides (mg/dL) 186.06186.7 168.66117.6 177.16119.4 180.96161.6
Medication Prescription
Antidepressants* 69.8% 43.2% 64.4% 64.2%
Anticonvulsants* 64.2% 21.6% 54.1% 54.9%
Benzodiazepines 24.9% 20.7% 23.0% 23.8%
First Generation Antipsychotics* 1.2% 19.8% 11.2% 6.7%
Second Generation Antipsychotics* 49.6% 63.1% 84.9% 60.7%
Lithium* 33.2% 1.8% 24.7% 26.1%
*p,0.05 between psychiatric groups.
doi:10.1371/journal.pone.0019298.t001
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diseases and conditions such as weight and exercise counseling for
obese patients, periodic monitoring of blood pressure, lipids and
glycemic control for patients with diabetes, arranging early follow-
up after discharge for patients with multiple anti-psychotic
medications, tobacco counseling and annual depression screening,
among others [39], is likely an important contributor to the higher
monitoring rates seen in our study. It is also likely that the patients
in our study had a higher comorbidity burden warranting
increased monitoring of various health parameters, including
metabolic syndrome components, irrespective of their mental
health diagnoses as has been seen previously in comparisons of
veteran and non-veteran patients [40,41]. One previous study of
veterans with bipolar disorder using second generation antipsy-
chotics revealed that roughly 50% had been monitored for
cholesterol and triglyceride levels and 70% for serum glucose levels
[18], which are rates closer to those seen in our study.
Among patients in our study who were completely monitored
for metabolic syndrome, our results confirmed the high prevalence
rates seen in previous studies, with prevalence more than double
that of the general population [5]. Several studies have shown
metabolic syndrome to be more prevalent among patients with
schizophrenia than the general population, with prevalence
among some recent American and Canadian studies ranging from
41% to 52% [6,31,42,43,44,45]. Although smaller in number,
other studies have shown increased prevalence of metabolic
syndrome among patients with bipolar disorder and schizoaffec-
Table 2. Monitoring of Metabolic Syndrome Components
(n = 1401).
Not Monitored (%) Monitored (%)
Metabolic Syndrome Components
Body Mass Index 46 (3.3) 1355 (96.7)
Hypertension 20 (1.4) 1381 (98.6)
High Density Lipoprotein 264 (18.8) 1137 (81.2)
Triglycerides 288 (20.6) 1113 (79.4)
Diabetes 104 (7.4) 1297 (92.6)
Any Metabolic Syndrome
Component
300 (21.4) 1101 (78.6)
All Metabolic Syndrome
Components
13 (0.9) 1388 (99.1)
Biological Variables
Blood Pressure 22 (1.6) 1379 (98.4)
Hemoglobin A1c 752 (53.7) 649 (46.3)
Blood Glucose 113 (8.1) 1288 (91.9)
Total Cholesterol 251 (17.9) 1150 (82.1)
Low Density Lipoprotein 377 (26.9) 1024 (73.1)
All Lipids 251 (17.9) 1150 (82.1)
doi:10.1371/journal.pone.0019298.t002
Table 3. Clinical and Demographic Characteristics of Patient Population by Metabolic Syndrome Monitoring Status.
Incomplete Monitoring (n=300) Complete Monitoring (n =1101)
Bipolar Disorder 61.0% 58.0%
Schizoaffective Disorder 21.7% 26.5%
Schizophrenia 17.3% 15.4%
Age (years) 54.6615.6 56.0611.2
Male 92.7% 92.5%
Married 29.8% 29.7%
Employed 42.0% 41.4%
Active Smoking 48.9% 52.6%
Global Assessment of Functioning 50.968.9 51.468.5
Hypertension Diagnosis* 23.7% 47.6%
Hypercholesterolemia Diagnosis* 20.3% 58.4%
Diabetes Diagnosis* 11.0% 24.4%
Stroke 3.7% 4.1%
Heart Failure 2.0% 2.8%
Coronary Artery Bypass Graft* 0.0% 0.9%
Percutaneous Transluminal Coronary Angioplasty 1.0% 2.0%
Primary Care Provider Visits 0.661.3 0.762.2
Service Connection (%) 65.9633.5 70.9632.7
Antidepressants* 56.0% 66.5%
Anticonvulsants* 43.3% 58.0%
Benzodiazepines* 17.3% 25.5%
Second Generation Antipsychotics* 50.3% 63.6%
Lithium 24.7% 26.4%
*p,0.05.
doi:10.1371/journal.pone.0019298.t003
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tive disorder as well, with a prevalence of 30 to 70% for bipolar
disorder [6,31,46,47,48] and 42.4% to 67% for schizoaffective
disorder [30,31]. However our study is among only a few studies
with large sample sizes which have examined metabolic syndrome
components among patients with serious mental illness. Our study
differs from other large studies such as the work by Rejas et al.
(2007) [49], de Hert et al. (2009) [50] and Shi et al. (2009) [51] in
that it includes patients with serious medical illnesses other than
just schizophrenia and also patients not using antipsychotic
medications. Another large study of 10,084 psychiatric outpatients
with schizophrenia, bipolar disorder, and depression was per-
formed by Correll et al. [6]. But unlike the Correll et al. study
which included only motivated and likely healthier individuals
willing to participate in a voluntary metabolic health fair, our
study is a cross-sectional analysis of all in- and out-patients coming
to the VA Medical Center over a two year period and likely
includes a broader spectrum of patients with major mental illnesses
irrespective of their disease severity. Although not statistically
significant, our study did show that patients with schizoaffective
and bipolar disorders trended towards higher prevalence of
metabolic syndrome than those with schizophrenia. These findings
are similar to a recent study of Australians with severe mental
illness [31], which found prevalence of metabolic syndrome to be
greatest among patients with bipolar or schizoaffective disorder
(both 67%), followed by schizophrenia (51%) and may be
suggestive of a link between affective symptoms and risk for
metabolic syndrome. Patients with affective symptoms (bipolar
disorder and schizoaffective disorder) are known to have
Hypothalamus-Pituitary-Adrenal (HPA) axis dysregulation [52]
which may result in hypercortisolism and contribute to weight
gain, hypertension and insulin resistance, a milieu favorable for the
development of metabolic syndrome. Additionally, use of certain
anti-depressant medications, which are more likely to be used in
patients with affective symptoms compared to those with
schizophrenia alone, has been associated with metabolic abnor-
malities [53].
According to the ADA/APA consensus statement, patients using
second generation antipsychotics should routinely have their BMI,
waist circumference, blood pressure, fasting plasma glucose and
fasting lipid profile monitored [9]. While the use of second
generation antipsychotics has been associated with metabolic
syndrome in several studies [7,8], psychiatric patients may also be
at risk for metabolic syndrome even in the absence of medication
use. Studies have revealed higher rates of impaired glucose tolerance
[27] and visceral fat distribution [28] in drug-naı¨ve patients with
schizophrenia compared to healthy controls. Psychiatric patients are
more likely to have reduced access to health care which combined
with socioeconomic factors limits the identification and management
of medical conditions such as metabolic syndrome [54]. Addition-
ally, the unaffected first degree relatives of patients with schizophre-
nia have higher rates of type 2 diabetes mellitus [55] suggesting a
possible genetic association between schizophrenia and metabolic
abnormalities, with the 5,10-methylenetetraydrofolate reductase
(MTHFR) gene a possible candidate for such a link [56,57]. Due
to the strong association between schizophrenia and cardiovascular
disease, the Mount Sinai Conference recommended that patients
with schizophrenia should be considered to be at high risk for
coronary heart disease [29] which would qualify them for more
frequent monitoring. Our study, however, suggests that in addition
to following these existing guidelines, providers should consider
screening all patients with serious mental illnesses for metabolic
syndrome due to the high prevalence rates of this condition observed
in patients with bipolar and schizoaffective disorders along with
those with schizophrenia.
Our study has certain limitations. Due to the cross-sectional
nature of this study, we are unable to draw any conclusions
regarding the causality of any associations seen in the study and
the population described in this study consists exclusively of
veterans who are predominantly male, white and over 50 years
old, which may not reflect the demographic characteristics of these
disorders outside the VA setting. However, this design allows us to
use a relatively large sample size to determine current monitoring
efforts in patients with different serious mental illnesses, including
those not using second generation antipsychotics. Secondly, we
modified the NCEP ATP III criteria (substituted a BMI$30 for
the waist circumference criterion) which is likely to have somewhat
altered the proportion of people in our sample categorized as
having metabolic syndrome. However, this modification is
consistent with previous studies of its kind [35], and reflects
current knowledge. Additionally, since providers are less likely to
measure waist circumference compared to BMI, our estimation of
monitoring rates of psychiatric patients is likely to be a more
conservative one than reality. Our study while looking at the rates
of monitoring for metabolic syndrome in the VA, did not account
for the possibility that patients may have been monitored for
different metabolic syndrome components at non-VA facilities.
However, the likelihood of this is low since we selected patients
who were actively being treated at the institution. Additionally,
there were no significant differences in the average service
connection and the number of PCP visits between patients who
were completely monitored and those who were not, suggesting
that both groups likely had similar degrees of engagement with
Table 4. Metabolic Syndrome Components for Completely Monitored Patients.
Bipolar (n =822) Schizophrenia (n =222) Schizoaffective (n =357) Total (n = 1101)
Body Mass Index* 46.5% 42.9% 53.8% 47.9%
Hypertension* 78.1% 68.8% 68.8% 74.2%
High Density Lipoprotein cholesterol* 48.4% 40.6% 54.1% 48.7%
Triglycerides 49.3% 42.4% 51.4% 48.8%
Glucose intolerance* 54.0% 58.8% 63.7% 57.3%
Metabolic Syndrome 57.1% 50.0% 61.0% 57.0%
Number of Criteria Met* 2.861.4 2.561.5 2.961.4 2.861.4
Age-Adjusted Metabolic Syndrome 46.6% 42.1% 56.7% 48.4%
*p,0.05 between psychiatric groups.
doi:10.1371/journal.pone.0019298.t004
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their providers, either at the VA or non-VA institutions. However,
we did not specifically measure potential provider based predictors
affecting monitoring of patients with serious mental illness for
metabolic syndrome. Due to the nature of the database query, the
mental health diagnosis and measurements of the different
metabolic syndrome criteria were likely not made during the
same clinical visits. Additionally, it is not possible to discern
whether or not DSM-IV criteria were strictly followed in
determining psychiatric diagnoses or whether or not these were
done in the setting of structured interviews.
Our study expands on existing literature by examining
monitoring of all five metabolic syndrome components among
patients with different psychiatric disorders including those not
using second generation antipsychotics. Our results show that
about 80% of patients with serious mental illness were monitored
for all metabolic syndrome components over a two year period.
However, monitoring appears to be significantly lower among
patients not prescribed second generation antipsychotics or
without previous diagnoses of hypertension and hypercholesterol-
emia. These results, coupled with the high prevalence of metabolic
syndrome – more than double that of the general population –
seen in our study, suggest a need to intensify monitoring of
metabolic syndrome among all patients with serious mental illness,
including for those not using second generation antipsychotics.
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